Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery
From the impact of environmental toxins and stress to the unique benefits of spore-based probiotics, this conversation demystifies the gut-thyroid connection and offers practical, science-backed solutions for healing and thriving
A nonpeptide oral GLP-1 receptor agonist, orforglipron data provided insight into a pair of phase 2 trials among patients with overweight or obesity and those with type 2 diabetes, respectively
WAYS TO SUPPORT MY WORK Massive compound shakeup00:00:43 Why compound users need this00:01:25 Sponsor, Shed obesity care00:02:11 Breaking news changed everything00:02:28 OTP semaglutide exclusive00:03:28 DDC list explained00:04:24 Novos lab findings00:09:57 302% dose shocker00:13:03 Catalents contamination mess00:16:33 Lillys B12 tirzepatide bombshell00:19:34 Is the molecule changing?00:21:46 New oral GLP-1 contender Cheap Zepbound Incoming for Medicare, But CMS Just Issued a Catch On this episode of the podcast, host Dave Knapp breaks down the latest updates on potential GLP-1 receptor agonists coverage for people on Medicare living with obesity
GLP-1 receptor agonists and cardiovascular outcomes in type 2 diabetes: Frontiers in Endocrinology , 14 , 9889489
US$ 23.53
US$ 21.88
US$ 29.75
